Hims & Hers Health Inc

HIMS remains in Stage 3 distribution with a recent support failure confirming medium-term bearish pressure. Price trades below declining 9/20/50 EMAs and the 200-day SMA, and despite being oversold near immediate support, the lack of a clear reversal structure warrants deferring bearish execution. We will trim into rallies around resistance at the 9/20 EMA zone.

• ↑Q2 revenue $753.2M (+38% YoY) with 300K net subs, totaling ~3M subscribers
• ↑Raised full-year guidance to $3.1–3.3B on strong subscriber momentum
• ↓Q2 loss per share $0.37 missed estimates of $0.05; FCF negative $68.2M